Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.

The Journal of infectious diseases - 30 Jan 2018

Leroux-Roels Geert, Cramer Jakob P, Mendelman Paul M, Sherwood James, Clemens Ralf, Aerssens Annelies, De Coster Ilse, Borkowski Astrid, Baehner Frank, Van Damme Pierre

Abstract excerpt

Background: We investigated safety and immunogenicity of 1-2 doses of different bivalent virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18- to 64-year-olds. Methods: On days 1 and 28, participants (n = 420) randomized to 14 equal groups received intramuscular control vaccine (hepatitis A) or 1 of 11 NoV formulations containing varying dosages of GI.1 and GII.4c genotype VLP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Formation
Share to Caliciviridae Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug-Related Side Effects and Adverse Reactions

Share to Healthy Volunteers

Share to Injections, Intramuscular

Share to Norovirus

Share to Viral Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 29140444
DOI: 10.1093/infdis/jix572
PMCID: PMC5853300

Genes

MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.PMID 29140444Read ↗

Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.Semantic proximity Read ↗

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trialSemantic proximity Read ↗

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccineSemantic proximity Read ↗

Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.Semantic proximity Read ↗

Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.Semantic proximity Read ↗

Safety and Immunogenicity of a VLP Poliovirus Vaccine: A Phase 1 TrialSemantic proximity Read ↗

An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults.Semantic proximity Read ↗

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.Semantic proximity Read ↗

An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled studySemantic proximity Read ↗

Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical TrialSemantic proximity Read ↗

The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trialSemantic proximity Read ↗

Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.